Broad Institute of MIT and Harvard

  • Creating a Fibrolamellar Cancer Dependency Map
    2020 – 2022

    Principal Investigator: Jesse Boehm, PhD, Institute Scientist, Director of the Broad Cancer Model Development Center

    This resource project is part of the Broad Institute’s Rare Cancer Dependency Map Initiative. It aims to create cell culture research models of FLC and utilize them to determine both a comprehensive list of potential drug targets for FLC and to identify existing drugs that may have therapeutic potential against FLC. Over 3 years the project is designed to:
    • In coordination with the FCF-sponsored BioBank, create a unified pipeline by which patients anywhere can direct living tissue to FLC researchers
    • Systematically develop conditions to propagate multiple fibrolamellar carcinoma (FLC) samples as organoid models in the Broad Institute’s Cancer Cell Line Factory laboratory using its combinatorial media screening technology
    • Create multiple publicly available, genomically characterized, and clinically annotated FLC cell models for the scientific community to support translational research
    • Identify ways to enhance the proliferation rates of FLC models developed by the Bardeesy Lab and others, creating new opportunities for translational research
    • Create a definitive list of the highest priority drug targets for FLC tumors together with predictive biomarkers
    • Determine whether any existing drugs, originally developed for any disease, may have repurposing potential in FLC
    • Empower the entire FLC research community by putting all data and biologist-friendly analysis tools freely available online, pre-publication at org.
    • Establish proof of concept for further scaleup of the Fibrolamellar Dependency Map Initiative in Years 3 and beyond, including genome-wide CRISPR screening and large scale drug repurposing in an expanded number of models.